title: Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
authors.affiliation: Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Geynisman
authors.affiliation: Department of Biostatistics Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
authors.forename: Eric A
authors.initials: EA
authors.lastname: Ross
authors.affiliation: Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA. Electronic address: elizabeth.plimack@fccc.edu.
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
mesh_terms: D000069501:Abiraterone Acetate / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D065088:Steroid Synthesis Inhibitors / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D050071:Bone Density Conservation Agents; D065088:Steroid Synthesis Inhibitors; D000069501:Abiraterone Acetate